Weight Loss Effectiveness What the Research Shows SAXENDA (liraglutide) (liraglutide) SAXENDA The first GLP-1 medication, Saxenda (liraglutide) was launched in 2010 by the same Danish pharmaceutical company Novo Nordisk which manufactures other diabetes medicines including insulin and Ozempic
What is GLP-3 RETA (Retatrutide)
Exposure to loud noise activates IL6 which results in additional inflammation
For patients who need semaglutide for obesity or weight management, that's a meaningful addition to the Canadian market
Connexins enable direct intercellular communication of metabolites, nucleotides, nutrients, and secondary messengers, regulating apoptosis, inflammation, and cellular growth, while also amplifying liver inflammation and cell death (Maes and Vinken 2017